Cisplatin is part of standard therapy for hepatoblastoma, a rare liver cancer, but hearing loss is a serious and permanent side effect. New research findings are summarized in a short video.
A phase 1 study of LB4330, a peptide fused to CLDN18.2 antibody targeting the tumor antigen associated (TAA) CD8+T cells in patients with advanced solid tumors. A phase II study of liposomal ...
RESEARCH TRIANGLE PARK, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results